Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q4VNC0

UPID:
AT135_HUMAN

ALTERNATIVE NAMES:
P5-ATPase isoform 5

ALTERNATIVE UPACC:
Q4VNC0; Q6UWS4; Q6ZWL0

BACKGROUND:
Probable cation-transporting ATPase 13A5, known alternatively as P5-ATPase isoform 5, is integral to the regulation of ion transport across cellular membranes. Its activity is essential for the proper functioning of cells, influencing various physiological processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Probable cation-transporting ATPase 13A5 holds the key to unlocking new therapeutic avenues. Given its central role in maintaining cellular equilibrium, targeting this protein could lead to innovative treatments for diseases linked to ion transport dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.